Edward L Atkinson

US Patent:

6566118, May 20, 2003

Filed:

Mar 15, 2000

Appl. No.:

09/526333

Inventors:

Edward M. Atkinson - Seattle WA
Ryan K. Takeya - Lynnwood WA
Ian L. Aranha - Seattle WA

Assignee:

Targeted Genetics Corporation - Seattle WA

International Classification:

C12N 702

US Classification:

435239, 4352351, 4353201

Abstract:

This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i. e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.

US Patent:

6995006, Feb 7, 2006

Filed:

Oct 30, 2001

Appl. No.:

10/020482

Inventors:

Edward M. Atkinson - Seattle WA, US
Victor P. Fung - Redmond WA, US
Perry C. Wilkins - Preston WA, US
Ryan K. Takeya - Lynnwood WA, US
Thomas C. Reynolds - Mercer Island WA, US
Ian L. Aranha - Seattle WA, US

Assignee:

Targeted Genetics Corporation - Seattle WA

International Classification:

C12N 7/02

US Classification:

435239, 4352351, 4353201

Abstract:

This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i. e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.

US Patent:

20050266567, Dec 1, 2005

Filed:

Jun 28, 2005

Appl. No.:

11/170269

Inventors:

Edward Atkinson - Seattle WA, US
Victor Fung - Redmond WA, US
Perry Wilkins - Preston WA, US
Ryan Takeya - Lynnwood WA, US
Thomas Reynolds - Mercer Island WA, US
Ian Aranha - Seattle WA, US

International Classification:

A61K048/00
C12N015/861
C12N007/00

US Classification:

435456000, 435235100, 435457000

Abstract:

This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.